PRA Health joins with clinical research network to improve vaccine studies

Seeking to accelerate the process of getting new vaccines to market, PRA Health Sciences ($PRAH) partnered with the Alliance for Multispecialty Research (AMR) to look for ways to help vaccine studies run more efficiently and effectively. The deal joins a leading contract research organization and a clinical research network, allowing the two "to make significant strides in implementing efficient solutions to smarter vaccine development," AMR CEO Brenda Atchison said in a statement. Release

Suggested Articles

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.